AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01325896
Drug: PEG-Intron sc injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.~PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.~Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse.
Trial: NCT04676607
Drug: SHR7390
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR7390
Trial: NCT03922815
Drug: rescue fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: a rescue dose of fentanyl 0,5 mcg per kilogram of body
Trial: NCT04469023
Drug: TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
Trial: NCT03781700
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 5 milligram tablets, 1 milligram per kilogram bodyweight per orally per day during 10 days, maximum 50 milligram per day.
Trial: NCT04179890
Drug: Afatinib (Gi(l)otrif®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) as first or second-line therapy.
Trial: NCT04179890
Drug: Afatinib (Gi(l)otrif®)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As first line therapy.
Trial: NCT00095238
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
Trial: NCT02011516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00677170
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
Trial: NCT04005716
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg was administered intravenously on Day 1 of each 21-day cycle to match tislelizumab.
Trial: NCT01348659
Drug: 7.2% NaCl/hydroxyethylstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
Trial: NCT01348659
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
Trial: NCT02856126
Drug: TACE regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion with lipiodol mixed with chemotherapy drugs (EADM , lobaplatin, and MMC ), and embolization with polyvinyl alcohol particles (PVA)
Trial: NCT02856126
Drug: HAIC Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Trial: NCT02457273
Drug: TLC 388
RxNorm normalized name: chlorpheniramine maleate / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Ed-TLC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
Trial: NCT00872027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills for 8 weeks
Trial: NCT03169660
Drug: Vascular endothelial growth factor trap-eye
RxNorm normalized name: endothelial growth factor A, vascular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months until 48 weeks after the initial injection.
Trial: NCT02072174
Drug: Anaferon for Children
RxNorm normalized name: Pediaclear Childrens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anaferon for children: For oral use.
Trial: NCT00768157
Drug: antiviral treatment (lamivudine or entecavir)
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
Trial: NCT02348905
Drug: ACTHAR Gel 80 units twice weekly.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
Trial: NCT01747044
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03486223
Drug: GSK2256294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug will be taken daily by mouth for 7 days.
Trial: NCT03486223
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken daily by mouth for 7 days.
Trial: NCT00822783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01749137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily subcutaneous infusion
Trial: NCT01572558
Drug: Conservative, non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
Trial: NCT02826902
Drug: propofol and remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
Trial: NCT02826902
Drug: desflurane and remifentanil
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced and maintained with desflurane and remifentanil
Trial: NCT01758432
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02298920
Drug: AZD0914
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
Trial: NCT00933972
Drug: RO4998452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg po single dose
Trial: NCT00793091
Drug: C-KAD Ophthalmic Solution
RxNorm normalized name: urea c-13 Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops applied daily for 120 days
Trial: NCT00793091
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 drops applied daily for 120 days
Trial: NCT00680017
Drug: ABT-335 plus rosuvastatin
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
Trial: NCT00680017
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
Trial: NCT02288377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03976349
Drug: BIIB094
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT03511963
Drug: HLX04 100 mg in 4 ml Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
Trial: NCT03511963
Drug: Avastin 100 mg in 4 ml Injection
RxNorm normalized name: Avastin 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg/kg iv (XELOX+HLX04) 5 mg/kg iv (mFOLFOX6 + HLX04)
Trial: NCT00709735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching propranolol) short-acting and long-acting capsules
Trial: NCT03584373
Drug: Ketorolac Oral Tablet [Toradol]
RxNorm normalized name: ketorolac Oral Tablet [Toradol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac is a prescribed NSAID with strong analgesic activity. Ketorolac will be administered post surgery to compare pain outcomes to that of Percocet.
Trial: NCT03584373
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen is an over-the counter pain medication that will be administered post surgery to compare pain outcomes to that of Percocet.
Trial: NCT03584373
Drug: Oxycodone Acetaminophen
RxNorm normalized name: acetaminophen / oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percocet is a prescribed opioid medication to manage pain. Percocet will be administered post surgery to compare pain outcomes to that of non-opioid analgesia.
Trial: NCT00084591
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02285452
Drug: Zingiberis Rhizoma plv.
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02285452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04341207
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin 500 mg on day 1 followed by 250 mg/day for 4 days
Trial: NCT01455129
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, once daily, inhaled by HandiHaler
Trial: NCT02691598
Drug: Infusion
RxNorm normalized name: INFUSION SET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
Trial: NCT02677324
Drug: ABT199
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCL-2 antagonist
Trial: NCT01895361
Drug: SelG1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01895361
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01883531
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The PLacebo is non respirable mannitol due to the big size particle
Trial: NCT04143711
Drug: DF1001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy agent targeting NK cells.
Trial: NCT01248611
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: nasally, dose titrated to effect
Trial: NCT02273609
Drug: Vitamin K antagonists (acenocoumarol or warfarin)
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.~No specific recommendation about treatment will be provided by sponsor.
Trial: NCT02402842
Drug: Docetaxel, Cisplatin and 5-Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
Trial: NCT03573102
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor once daily
Trial: NCT00091507
Drug: GIK
RxNorm normalized name: Surgikos Tip Cleaner
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
Trial: NCT00091507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
Trial: NCT04811911
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Trial: NCT03583242
Drug: Antiangiogenic Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 Intravitreal injections of 0.05 ml of Aflibercept (40 mg/ml) during 3 months (one per month) The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Trial: NCT03583242
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
DrugBank: Corticosterone (DB04652)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Injection of dexamethasone intravitreal implant 0.7mg. The clinical management of the patients will be adapted to the treatment standards of the Ophthalmology Service of the Hospital de la Santa Creu and Sant Pau, without the realization of this study influencing such process.
Trial: NCT03607656
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine tablet
Trial: NCT04025476
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV and oral steroids
Trial: NCT00351078
Drug: PTC124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-,4-, and 8-mg/kg PO first 14 days 10-, 10-, and 20-mg/kg TID second 14 days
Trial: NCT00879931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (NaCl 0.9%)
Trial: NCT02671162
Drug: Fumaria
RxNorm normalized name: Fumaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day each time 2 capsules before eating meal for 8 weeks.
Trial: NCT00277641
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: identical tablets to study drug
Trial: NCT00420641
Drug: GSK372475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK372475 1.0-1.5 mg/day
Trial: NCT05484687
Drug: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer 1.5 mg/kg lidocaine
Trial: NCT04345887
Drug: Spironolactone 100mg
RxNorm normalized name: SPIRONOLACTONE 100MG TAB
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2x100 mg spironolactone for 5 consecutive days
Trial: NCT04345887
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x1 placebo tablet
Trial: NCT03562377
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo contains the same excipients in the same concentration only lacking tralokinumab.
Trial: NCT02937662
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
Trial: NCT02937662
Drug: Physician-Directed Regimens without Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
Trial: NCT00005893
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01222559
Drug: co.don chondrosphere®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
Trial: NCT02121405
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
Trial: NCT02120456
Drug: LEO 43204
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02120456
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00741429
Drug: Technosphere Insulin Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects previously treated with Technosphere Insulin Inhalation Powder
Trial: NCT00741429
Drug: Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects previously treated with other anti-diabetic medications
Trial: NCT00582816
Drug: conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
Trial: NCT03210688
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet prednisolone
Trial: NCT03422796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT03118518
Drug: Antiarrhythmic drug
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drug initiation
Trial: NCT04529096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01079702
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
Trial: NCT01710371
Drug: 10% Arginine Hydrochloride-R-Gene 10
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00065559
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02217527
Drug: Placebo pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
Trial: NCT01722227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01039584
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal cream
Trial: NCT03133065
Drug: treatment of HCV with oral direct acting antiviral therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
Trial: NCT01039584
Drug: Gynazole 1 vaginal cream
RxNorm normalized name: Gynazole-1 Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vaginal cream
Trial: NCT04266301
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A dose of Placebo 800 mg will be administered intravenously every 4 weeks (Q4W).
Trial: NCT04078659
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive fentanyl 1-2 mcg/kg before induction of anaesthesia
Trial: NCT05391893
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: these patients will receive traditional treatments at provider discretion. They must receive at least one intravenous medication for atrial fibrillation with rapid ventricular response. This will be a heterogenous group of patients receiving digoxin, amiodarone, various beta-blockers, and intravenous diltiazem without oral diltiazem.
Trial: NCT03169790
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Trial: NCT03169790
Drug: leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Trial: NCT03906695
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral decitabine 5mg + cedazuridine